Patients are at the center of everything we do at GlycoMimetics. Through collaboration with our clinical partners, we are conducting clinical studies that explore the use of product candidates developed by our scientists in multiple oncology and other indications. Our central goal is to obtain the data required for review and approval by regulatory authorities, such as the U.S. Food and Drug Administration.
Ongoing Trials:
- Uproleselan (GMI-1271): As of November 2021, completion of enrollment is imminent for the company-sponsored pivotal Phase 3 trial (NCT03616470) in patients with relapsed/refractory acute myeloid leukemia who are considered to be medically eligible to receive intensive chemotherapy. Top line results from this trial are anticipated after year-end 2022.
- Uproleselan (GMI-1271) is being evaluated by the National Cancer Institute as a potential new treatment for newly diagnosed AML patients fit for chemotherapy (NCT04964505). Completion of enrollment of the Phase 2 portion of the Phase 2/3 study is anticipated by year-end 2021, allowing for an interim analysis of Event-Free Survival.
- GMI-1359, a dual antagonist of E-selectin and CXCR4, has recently been evaluated in a Phase 1b study at Duke University in patients with hormone receptor positive metastatic breast cancer (NCT04197999). Interim results from this trial were reported at the AACR meeting in April 2021 showing clear evidence of on-target biological effects.
Other Clinical Programs:
- To learn more about other clinical trials involving our product candidates, please visit ClinicalTrials.gov: a publicly and privately supported registry of clinical studies involving human participants conducted around the world. To find information on trials run by GlycoMimetics, our development partners, or by independent investigators, use the “Search for Studies” function and enter the product candidate’s name (e.g., uproleselan).